JWCA has advised nEUROCRINE on capital market transactions with OVER $300 mILLION in transaction Value
May 2022: JWCA advises Neurocrine Biosciences on the repurchase of its convertible notes
November 2020: JWCA advises Neurocrine Biosciences on the repurchase of its convertible notes